Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

Table 3 Detailed information of discordant cases for PD-L1 expression among paired samples

No.	Specimen 1					Time interval	Specimen 2
No.	Type	VTC	Treatment	Staining intensity	PD-L1%	Time interval	Type	VTC	Treatment	Staining intensity	PD-L1%
1	Surgical resection (lung)	10,000	NT	3+	70	18.5 m	MPE	10,000	AIT^a	3+	40
2	Subaxillary mass biopsy	790	CM, AIT	1+	15	10.2 m	MPE	10,000	CM^a, AIT	3+	90
3	CTG-CN (lung)	400	NT	1+	45	5.1 m	MPE	100,000	TGT^a	3+	90
4	CTG-CN (lung)	5000	NT	1+	< 1	1.6 m	MPE	10,000	CM^a, EBRT^a	3+	> 90
5	Surgical resection (LN)	30,000	NT	1+	15	3 d	MPE	56,000	NT	2+	70
6	MPE	320	CM	1+	20	0 d	Pleural biopsy	240	CM	2+	70
7	MPE	5000	NT	2+	50	0 d	Surgical resection (LN)	10,000	NT	2+	5
8	MPE	6000	NT	2+	55	0 d	Endobronchial FB	450	NT	1+	15
9	MPE	150,000	NT	3+	> 90	1 d	Endobronchial FB	234,000	NT	1+	10
10	MPE	80,000	NT	3+	> 90	2 d	CTG-CN (lung)	37,100	NT	2+	20
11	MPE	500	NT	3+	> 90	2 d	Endobronchial FB	400	NT	1+	40
12	MPE	30,000	NT	3+	> 90	4 d	Pleural biopsy	1060	NT	2+	35
13	MPE	125	NT	2+	20	6 d	Pleural biopsy	450	NT	1+	< 1
14	MPE	10,000	NT	3+	90	10 d	Lymph node biopsy	550	NT	1+	2
15	MPE	1540	NT	1+	20	19.1 m	Pleural biopsy	4520	TGT^a	1+	< 1

Abbreviation: VTC viable tumor cells, MPE malignant pleural effusion from thoracentesis, PD-L1 programmed cell death ligand-1, CTG-CN computed tomography-guided core needle biopsy, FB forceps biopsy, NT no treatment, CM chemotherapy, TGT targeted therapy, AIT adoptive cellular immunotherapy, EBRT external beam radiotherapy; ^adifferent from previous treatments; Specimen 1 obtained earlier than specimen 2

ISSN: 1471-2407